Radiopharmaceuticals are quietly becoming the part of oncology that no longer sits in the hospital basement—capital, M&A desks, and regulators have all joined the tour. For investors, the space now looks less like a scientific hobby and more like a pipeline strategy you can actually model in Excel—albeit with a few isotopic caveats.
From Niche To Necessary
Radiopharmaceuticals, once relegated to diagnostic scans, are now central to “theranostics” strategies that pair imaging with targeted treatment in the same molecular package. Global market estimates put the sector in the mid–single-digit billions today, with projections toward roughly 14–22 billion dollars over the next decade, depending on whose forecast your investment committee prefers.
Demand is being propelled by aging populations, oncology’s shift toward precision medicine, and growing comfort with radionuclide therapies that deliver radiation directly to tumors while sparing most of the surrounding real estate. At the same time, analysts flag that the short half‑life of many isotopes and strict regulatory handling rules mean this is not a business you scale from a garage—or even a particularly ambitious warehouse.
M&A Goes Nuclear
If there is a tell for where big pharma thinks oncology is headed, Bristol Myers Squibb’s (BMY) $4.1 billion purchase of RayzeBio is a strong candidate. The deal delivered an actinium‑based radiopharmaceutical platform and a pipeline led by RYZ101, now advancing in gastroenteropancreatic neuroendocrine tumors and small cell lung cancer, along with a state‑of‑the‑art manufacturing footprint.
They are not alone. Telix’s (TLX) acquisition of imaging assets from ImaginAb and Lantheus’ $750 million move for Life Healthcare’s radiopharma business underscore a broader land grab by companies eager to control both isotopes and intellectual property before valuations fully catch up with expectations. For deal desks, radiopharma has become the rare category where M&A simultaneously buys science, supply chain, and a head start in regulatory familiarity—three birds with one radioactive stone.
Pluvicto And The Proof Point
If investors were waiting for a proof‑of‑concept commercial story, Novartis’ Pluvicto has largely obliged. Initially approved for post‑chemotherapy metastatic castration‑resistant prostate cancer, the drug has since expanded into earlier lines of therapy, tripling its eligible patient pool and driving quarterly sales into the hundreds of millions.
Management now talks openly about a peak sales target north of 5 billion dollars, as new data show meaningful reductions in risk of progression or death and an expanding global footprint across more than 20 countries. To smooth logistics, Novartis has even introduced pre‑filled syringes and is building out production sites in Japan and China—because nothing says “this is real” quite like capex in multiple time zones.
IPO’s Heating Up
Recently, radiopharma specialist Aktis Oncology pulled Big Pharma heavyweights back into its cap table with an upsized $175 million Series B led by RA Capital Management and joined by RTW Investments, Janus Henderson Investors, and strategic investors Bristol Myers Squibb, Eli Lilly, and Merck’s MRL Ventures Fund. The financing, which lifted Aktis’ total capital raised to roughly $346 million and left the company with about $300 million in cash, is earmarked to advance its alpha-emitting radiopharmaceutical pipeline, including lead Nectin‑4–targeting candidate AKY‑1189 for solid tumors.
Aktis’ precise post-Series B private valuation has not been publicly disclosed, though market trackers note the round without attaching a specific price tag, suggesting only that it is a late-stage, heavily syndicated private biotech financing. In its newly filed U.S. IPO registration, the company has not yet set the number of shares or price range, so a proposed IPO valuation remains undefined, with analysts only indicating that Aktis could be an early 2026 test case for renewed biotech IPO appetite rather than assigning a concrete deal value at this stage.
Naya Therapeutics Steps Into The Beam
One of the more intriguing pure‑play innovators in this field is Naya Therapeutics, a clinical‑stage company built around astatine‑211 targeted alpha therapies and NK‑cell‑engaging bifunctional antibodies. Naya’s lead radiopharmaceutical programs center on GPC3‑targeted alpha therapies for hepatocellular carcinoma, including NY‑700 and NY‑703, which aim to mop up residual disease and micrometastases in patients who have already tested the limits of standard immunotherapies.
To solve the isotope bottleneck, Naya has stitched together a decentralized manufacturing strategy, partnering with Atley Solutions and Alpha Nuclide to secure scalable At‑211 supply and deploy Atley’s C100 production modules near treatment centers—a logistical twist that reads like Pluvicto’s infrastructure play, but tuned for a different radionuclide. Layered on top of this, the company’s FLEX‑NK bispecific antibody platform and NK‑cell collaborations give it a dual‑modality angle: radiopharmaceuticals to irradiate the tumor and engineered immune engagement to keep pressure on whatever cells might otherwise try to stage a comeback.
Infrastructure: The New Moat
Behind the headlines sits an unglamorous but decisive factor: infrastructure. Radiopharmaceuticals depend on a fragile isotope supply chain, specialized manufacturing, and cold‑chain logistics that make biologics look straightforward by comparison.
As a result, capital in 2025 is increasingly concentrating in “full‑stack” players—those that control isotopes, manufacturing, and clinical programs under one roof, or at least under one very detailed services agreement. Legal and industry analyses point to continued consolidation as firms race to lock in capacity and regulatory know‑how before bottlenecks begin to cap revenue rather than support it.
Investment Lens: Opportunity With Half‑Life
For equity investors and private capital, radiopharmaceuticals now combine three attractive themes: oncology, precision medicine, and defensible infrastructure. Market research pegs compound annual growth in the high single to mid‑teens percentage range through the end of the decade, with therapeutic radiopharmaceuticals outpacing diagnostics as pipelines mature.
The risks, of course, are not merely radiologic. Regulatory complexity, manufacturing missteps, and execution challenges around global rollouts can all compress the story’s multiple faster than an isotope decay curve. Still, if the past two years of deals, Pluvicto’s sales trajectory, and the emergence of focused players like Naya are any indication, radiopharmaceuticals have moved from speculative subplot to main character status—leaving investors with one lingering question: in a market this hot, is under‑exposure the real radioactive asset on the balance sheet.
Sources
[1] Radiopharmaceutical Industry Update: Q4/Q1 (2024-2025) https://www.mcguirewoods.com/client-resources/alerts/2025/4/radiopharmaceutical-industry-update-q4-q1-2024-2025/
[2] Innovations Drive Growth in $21.9 Billion Radiopharmaceutical Market by 2029 https://finance.yahoo.com/news/innovations-drive-growth-21-9-093000312.html
[3] Radiopharmaceuticals Market Size to Hit USD 14.44 Billion … https://www.precedenceresearch.com/radiopharmaceuticals-market
[4] What’s Hot in 2025: Radiopharmaceuticals | Eureka blog https://www.criver.com/eureka/whats-hot-2025-radiopharmaceuticals
[5] Radiopharmaceutical Market Size, Growth & Trends By 2033 https://straitsresearch.com/report/radiopharmaceutical-market
[6] Bristol Myers Squibb agrees to acquire RayzeBio for $4.1bn https://www.pharmaceutical-technology.com/news/bristol-myers-squibb-to-acquire-rayzebio/
[7] Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform … https://www.businesswire.com/news/home/20231225781528/en/Bristol-Myers-Squibb-Adds-Premier-Radiopharmaceutical-Platform-with-Acquisition-of-RayzeBio
[8] Bristol Myers Squibb acquires RayzeBio for $4.1bn https://www.pharmaceutical-technology.com/news/bristol-myers-squibb-rayzebio/
[9] Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Adds-Premier-Radiopharmaceutical-Platform-with-Acquisition-of-RayzeBio/default.aspx
[10] Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio | RayzeBio https://investors.rayzebio.com/news-releases/news-release-details/bristol-myers-squibb-adds-premier-radiopharmaceutical-platform
[11] 2025 Biopharma Surge: Radiopharmaceutical M&As Heat Up https://www.linkedin.com/pulse/rebooting-ma-season-next-hot-territory-biopharmaceuticals-xyxqe
[12] Novartis’ Pluvicto wins key FDA nod toward $5B-plus sales target https://www.fiercepharma.com/pharma/novartis-prostate-cancer-drug-pluvicto-wins-key-fda-nod-toward-5b-plus-sales-target
[13] Novartis’ Pluvicto continues to show data and sales muscle – BioWorld https://www.bioworld.com/articles/702200-novartis-pluvicto-continues-to-show-data-and-sales-muscle
[14] Novartis’ Pluvicto picks up speed, delivers another trial win https://www.fiercepharma.com/pharma/novartis-pluvicto-finally-picks-speed-delivers-another-trial-win-early-prostate-cancer
[15] Novartis’ Pluvicto Heavywork Proves Radiopharma Can Succeed https://www.biospace.com/business/novartis-pluvicto-heavywork-proves-radiopharma-can-succeed
[16] PSMAddition data show Novartis Pluvicto™ delays progression to … https://www.novartis.com/us-en/news/media-releases/psmaddition-data-show-novartis-pluvictotm-delays-progression-end-stage-prostate-cancer
[17] Home | NAYA Therapeutics: Pioneering the Next Generation of … https://www.nayatx.com
[18] Our Platform / Science – NAYA Therapeutics https://www.nayatx.com/copy-of-about-us
[19] NAYA Therapeutics Expands its Hepatocellular Carcinoma (HCC … https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-expands-its-hepatocellular-carcinoma-hcc-pipeline-with-first-in-cla-1040403
[20] Astatine-211 Targeted Alpha Therapies – NAYA Therapeutics https://www.nayatx.com/astatine-211-targeted-alpha-therapies
[21] NAYA Therapeutics to partner with Atley Solutions to accelerate the … https://atley.com/news/naya-therapeutics-to-partner-with-atley-solutions-to-accelerate-the-development-and-commercialization-of-nayas-at-211-radiopharmeceuticals/
[22] NAYA Announces Partnership with Alpha Nuclide to Support … https://firstwordpharma.com/story/6320192
[23] ONK Therapeutics and NAYA Biosciences Announce Research … https://www.onktherapeutics.com/onk-therapeutics-and-naya-biosciences-announce-research-partnership-to-advance-combination-therapy-of-optimally-engineered-off-the-shelf-natural-killer-cell-therapies-and-flex-nk-bispecific-a/
[24] NAYA Therapeutics Partners With IONETIX to Build a US Production … https://firstwordpharma.com/story/5991246
[25] Mid-Year Radiopharma Trend Pulse – H1 2025 https://www.linkedin.com/pulse/mid-year-radiopharma-trend-pulse-h1-2025-roger-estafanos-4s2de
[26] Council Post: Radiopharmaceutical Industry Trends Shaping 2025 https://www.forbes.com/councils/forbesbusinesscouncil/2025/02/20/radiopharmaceutical-industry-trends-shaping-2025/
[27] Innovations Drive Growth in $21.9 Billion Radiopharmaceutical Market by 2029 https://www.globenewswire.com/news-release/2025/05/02/3073122/28124/en/Innovations-Drive-Growth-in-21-9-Billion-Radiopharmaceutical-Market-by-2029.html
[28] NAYA Biosciences Announces Development of NY-500, a Novel AI … https://invofertility.com/naya-biosciences-announces-development-of-ny-500-a-novel-ai-optimized-pd-1-x-vegf-bifunctional-antibody/
[29] NAYA Therapeutics – LinkedIn https://www.linkedin.com/company/naya-therapeutics
[30] NAYA Therapeutics Partners with Atley Solutions on Astatine-211 … https://www.pharmaindustrial-india.com/news/naya-therapeutics-partners-with-atley-solutions-on-astatine-211-radio-pharmaceuticals
[31] NAYA Therapeutics to Present at the Network for Optimized Astatine … https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-to-present-at-the-network-for-optimized-astatine-labeled-radiopharm-1096632
[32] NAYA Biosciences has Expanded the Oncology Pipeline with … https://oncodaily.com/insight/219228
[33] NAYA Therapeutics, Inc. – Drug pipelines, Patents, Clinical trials https://synapse.patsnap.com/organization/4f4fc0b9cb1f12f29f640a14d35c8f9d
[34] Day One – 2nd TRP Target Selection & Drug Design Summit 2026 https://targeted-radiopharma-target-selection-drug-design.com/day-one/
[35] NAYA Therapeutics Enters into Definitive Agreements to Regain Full … https://finance.yahoo.com/news/naya-therapeutics-enters-definitive-agreements-130000468.html
[36] NAYA Biosciences Develops AI-Optimized PD-1 x VEGF Antibody … https://synapse.patsnap.com/article/naya-biosciences-develops-ai-optimized-pd-1-x-vegf-antibody-ny-500
[37] NAYA Therapeutics Partners with Alpha Nuclide to Advance … https://trial.medpath.com/news/e4c6693261bb40b5/naya-therapeutics-partners-with-alpha-nuclide-to-advance-astatine-211-therapy-for-hepatocellular-carcinoma-in-china
[38] Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha … https://pmc.ncbi.nlm.nih.gov/articles/PMC12468084/
[39] Published study on 161Tb-PSMA-617 therapy in mCRPC in Journal … https://www.linkedin.com/posts/ceren-sezgin-5968596a_thrilled-to-share-that-our-study-on-activity-7368271330405801987-QHUp
